Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines

Abstract Initial in vitro investigations demonstrated type I interferons (IFNs: IFN-α, IFN-β) to inhibit replication of SARS coronavirus (SARS-CoV), but found the nucleoside analogue ribavirin ineffective in Vero cells. In this report, ribavirin was shown to inhibit SARS-CoV replication in five different cell types of animal or human origin at therapeutically achievable concentrations. Since clinical anti-SARS-CoV activity of type I interferons or ribavirin is limited, we investigated the combination of IFN-β and ribavirin. Determination of the virus yield indicated highly synergistic anti-SARS-CoV action of the combination suggesting the consideration of ribavirin plus IFN-β for the treatment of SARS.

[1]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[2]  Hisashi Moriguchi,et al.  Treatment of SARS with human interferons , 2003, The Lancet.

[3]  A. Colecchia,et al.  Safety of interferon beta treatment for chronic HCV hepatitis. , 2004, World journal of gastroenterology.

[4]  J. Dennis,et al.  Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. , 2003, JAMA.

[5]  B. Lim,et al.  Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs , 2004, Emerging infectious diseases.

[6]  W. Seto,et al.  Severe acute respiratory syndrome: scientific and anecdotal evidence for drug treatment. , 2004, Current opinion in investigational drugs.

[7]  Y. Guan,et al.  Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings , 2004, Thorax.

[8]  H. Doerr,et al.  Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus , 2003, The Lancet.

[9]  H. Schwalbe,et al.  Retroviral Vectors Pseudotyped with Severe Acute Respiratory Syndrome Coronavirus S Protein , 2004, Journal of Virology.

[10]  F. Aoki,et al.  Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α , 2004, The Journal of infectious diseases.

[11]  Y. Guan,et al.  In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds , 2004, Journal of Clinical Virology.

[12]  P. Baer,et al.  Isolation of proximal and distal tubule cells from human kidney by immunomagnetic separation. Technical note. , 1997, Kidney international.

[13]  Christian Drosten,et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[14]  Gideon Koren,et al.  Ribavirin in the treatment of SARS: A new trick for an old drug? , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[15]  H. Doerr,et al.  Role of interferons in the treatment of severe acute respiratory syndrome , 2004, Expert opinion on biological therapy.

[16]  Pan‐Chyr Yang,et al.  Temporal Relationship of Viral Load, Ribavirin, Interleukin (IL)—6, IL-8, and Clinical Progression in Patients with Severe Acute Respiratory Syndrome , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[18]  A. Colecchia,et al.  Safety of interferon β treatment for chronic HCV hepatitis , 2004 .